14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
INVA vs VOR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
INVA Overall Winner
6-Pillar Tally: INVA 5 – 1 VOR
Matrix Metrics: INVA 6 – 4 VOR
As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INVA carries a Unified Composite Score of 48.9/100 (HOLD) at $18.49 (8.8x Forward P/E, 39.5% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. INVA 48.9/100 HOLD), INVA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (39.5% vs. 0.0% operating margin) and revenue trajectory (-1.6% vs. +0.0% YoY).
Technical & Structure Timing Caution: INVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INVA vs VOR. Trailing 12-month operating profitability (INVA 39.5% vs VOR 0.0%) and valuation multiples (INVA 8.8x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.3B market capitalization and 39.5% operating margin.
OpEx & R&D Reinvestment37.5% of Rev ($164M)
90D Engineering Disclosures0 Published
VOR Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ INVA vs VOR Key Questions & Quantitative Answers
As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over Vor Biopharma Inc. (VOR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INVA carries a Unified Composite Score of 48.9/100 (HOLD) at $18.49 (8.8x Forward P/E, 39.5% operating margin), whereas VOR carries 57.8/100 (HOLD) at $18.97 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VOR currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. INVA 48.9/100 HOLD), INVA captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (39.5% vs. 0.0% operating margin) and revenue trajectory (-1.6% vs. +0.0% YoY). Technical & Structure Timing Caution: INVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INVA leads the Growth & Scale pillar: INVA posts -1.6% YoY revenue growth and +590.4% YoY earnings growth on $438M TTM revenue (77.0% gross margin, 39.5% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, INVA generates $438M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, INVA deploys 37.5% of Rev ($164M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.
INVA screens cheaper on headline valuation multiples. INVA trades at 8.8x Forward P/E, 8.1x Trailing P/E, 2.82x PEG, and 2.4x EV/Revenue (41.6% FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INVA (18.0% ROE) versus VOR (-125.4% ROE) capital efficiency.
In options market volatility and institutional positioning, INVA carries 23.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 37% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.